2Morrow develops, licenses, and distributes behavioral digital health and DTx products. With over a dozen published studies and one of the few Phase III RCT in digital health, 2Morrow takes an evidence-based approach to staying healthy. 2Morrow has employee wellness programs in a market that support population wellness and well-being initiatives. 2Morrow has multiple products in the pipeline that expand on their work in substance use and for people living with chronic conditions.

4baseCare provides precision oncology solutions with advanced genomics to help cancer patients. The company focuses on leveraging advanced genomic technologies to provide personalized cancer treatment solutions. By analyzing the genetic profile of cancer patients, 4baseCare aims to identify targeted therapies that are more effective and have fewer side effects compared to traditional treatments. Their services include genomic testing, data interpretation, and personalized treatment recommendations, which are designed to improve patient outcomes and support healthcare providers in delivering precision medicine. The company collaborates with various stakeholders, including hospitals, research institutions, and pharmaceutical companies, to advance cancer care and research.

Access Vascular has developed a disruptive technology using a novel material process intended to significantly reduce the blood component accumulation (thrombosis or blood clotting) that leads to occlusions and infections. Over the last three years, Access Vascular’s technology has demonstrated the potential for superior clinical outcomes and lower healthcare costs compared with existing technologies. For patients, their solutions are predicted to decrease morbidity, shorten hospital stays, advance treatment, and minimize pain. Their technology has the potential to address a range of clinical needs in a variety of indications. Access Vascular is focused initially on launching their HydroPICC, a peripherally inserted central catheter with superior material performance over the current lagging technology.

Aevice Health is a pioneering company focused on transforming the management of chronic respiratory diseases through its innovative product, the Aevice MD, a non-invasive wearable stethoscope. This device allows for continuous monitoring of lung sounds and vital signs, enabling healthcare professionals to track patient responses to treatment plans effectively. By providing hospital-quality insights directly from home, Aevice Health enhances accessibility to respiratory care, reduces the risk of adverse events, and drives patient engagement. The company has received multiple awards for its innovation in digital health, positioning it as a leader in the respiratory care market.

Aksense is developing a quick blood test to help people who are suffering from healthcare-associated infections, with testing these infections in one minute with a portable electronic biosensor, without a lab or expert, saving lives, time, and money. Contact us to find out more.

Alva Health is a Yale technology startup that is developing a wearable neuromonitoring platform with the first indication in real-time stroke detection, for payers that provide healthcare coverage to populations with high incidence of cardiovascular disease and stroke. Alva Health recently raised $1.5MM in non-dilutive funding from the National Science Foundation and National Institutes of Health SBIR programs to develop their pre-production device. Their founders have a track record of inventing and validating neurotechnologies through the FDA, as well as B2B sales in the medical device industry, and they were named one of the Top 50 MedTech startups worldwide in 2021 by MedTech Innovator.

Ankr Health uses AI and telemedicine to automate side effect management in cancer and surgical clinics. Founded in 2022 and is based in San Francisco, CA.

Anumana is an AI-driven company that develops ECG algorithms enabling early disease diagnosis and intervention. Anumana harnesses industry-leading AI and translational science to decode the electrocardiogram (ECG) – like a deep predictive tool and biomarker of disease, empowering care providers to help patients early.

Aopia Biosciences is a biotechnology business focused on developing cutting-edge bioengineering solutions and technologies for biomedical research, diagnostics, and therapeutic applications.

Astek Diagnostics is a medical device company developing the JIDDU system, an innovative clinical diagnostics platform that provides rapid infection confirmation for urinary tract infections (UTIs) and antibiotic sensitivity indication within one hour. This platform significantly enhances diagnostic speed and accuracy, reducing patient complications and healthcare costs. With a focus on addressing the growing issue of antibiotic-resistant UTIs, Astek aims to transform the standard of care, particularly benefiting women who are more prone to UTIs. The company is currently in partnership with key healthcare institutions and is on track for market entry in 2025, showcasing strong initial results and a commitment to improving patient care.

Atom Bioworks is a developer of a pattern-recognition enabled DNA-antibody-mimic rational design platform for sensing and therapeutics of infectious diseases.